Fourth Annual CES Asia Opens Tomorrow
CES Asia™ 2018 – the premier destination for the consumer technology industry in Asia – kicks off tomorrow with its fourth annual event. One of the fastest growing tradeshows in Asia, this year’s innovation event will showcase the entire technology ecosystem, across 20 product categories, featuring technology that is improving lives around the world. Attendees can take full advantage of everything CES Asia 2018 has to offer by experiencing dedicated show floor areas, keynote addresses from industry leaders, events, award programs and a comprehensive conference program.
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is driving the expansion of transformative technologies such as 5G connectivity, artificial intelligence (AI), augmented & virtual reality and vehicle technology into new industries and markets. The event runs through Friday, June 15 at the Shanghai New International Expo Centre (SNIEC). Register here.
Don’t miss the action at CES Asia 2018. Top highlights include:
- Learn how 5G will transform industries and feel the future of mobile with bendable displays, face recognition, bezel-less and button-less screens.
Artificial Intelligence (AI)
- Experience the latest in AI infrastructure in a newly dedicated exhibit space featuring top AI innovators.
Augmented/virtual reality (AR/VR)
- Experience the far-reaching effect of altered perception and immersive multimedia.
- Disrupting markets and bringing game-changing innovation to business, healthcare, education and more.
- Startup Park, on the show floor will feature more than 100 startups from 15 countries, regions and territories.
- Explore the latest in concept cars and connected vehicles in expanded hall, outdoor area and test tracks.
CES Asia provides an international stage for top CEOs and senior-level leaders to forecast and envision the future of tech across multiple industries. This year, some of the industry’s top leaders will take the CES Asia keynote stage:
Gary Shapiro, president and CEO, CTA, and Zhou Houjian,
9:30-10:30 AM June 13 – Kerry, Level 3, Shanghai Ballroom 2-3
Kevin Ho, president, Handset Product Line, Huawei
1:15-2:15 PM June 13 – Kerry, Level 3, Shanghai Ballroom 2-3
Dr. Carsten Breitfeld, CEO and co-founder, BYTON, and Dr.
Daniel Kirchert, president and co-founder, BYTON
4-5 PM June 13 – Kerry, Level 3, Shanghai Ballroom 2-3
Miffy Chen, general manager, Alibaba A.I. Labs
9:30-10:30 AM June 14 – Kerry, Level 3, Shanghai Ballroom 2-3
Lenovo’s Ablikim Ablimit, vice president for strategy and business
development, China Geo, and Dr. Chang Cheng, vice president,
Lenovo Group, and head of Lenovo China Mobile Business Unit
1:30-2:30 PM June 14 – Kerry, Level 3, Shanghai Ballroom 2-3
China’s Powerful Startup Economy
4-5 PM June 14 – Kerry, Level 3, Shanghai Ballroom 2-3
CES Asia 2018 is the proving ground for transformative tech. It also houses the region’s most innovative events and prestigious awards, such as:
Asia Innovation Awards
presented by Suning
SNIEC, Hall N4
presented by Living in Digital Times
Noon-12:45 PM June 13 – SNIEC, Hall N3, N3 Stage, Booth #3384
CES Asia Startup Awards
presented by TechNode
1-4 PM June 13 – SNIEC, Hall N4, Startup Park Stage
on the Runway
presented by Living in Digital Times
3-3:30 PM June 13 – SNIEC, Hall N3, N3 Stage, Booth #3384
of CES Asia Awards
presented by ZOL
Noon-1 PM June 14 – SNIEC, Hall N3, Booth #3086
CES Asia 2018 conference programming will feature thought-leaders and industry pioneers, highlighting emerging trends throughout the Asian market. Discussion topics include blockchain technology, AI, AR/VR, smart devices and more. Visit CESAsia.com for the full schedule of conference sessions.
Note to Editors:
High-definition video b-roll is available for easy download on CESbroll.com . Visit the CES Asia photo gallery for the latest pictures from CES Asia 2018. Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at bmoon@CTA.tech or +1 703-907-4351.
CES Asia Exhibit Hours:
- Wednesday, June 13: 9 AM – 5 PM
- Thursday, June 14: 9 AM – 5 PM
- Friday, June 15: 9 AM – 3 PM (Open to Consumers)
What to bring with you:
- For overseas media: Bring your confirmation letter, J1 or J2 Visa and a government-issued photo ID
- For resident correspondents from a permanent office of foreign news agencies in mainland China: Bring your confirmation letter, ID card and employee card that shows your identity as a resident correspondent
- For media from Hong Kong and Macau: Bring your confirmation letter, Mainland Travel Permit for Hong Kong and Macau Residents and Hong Kong/Macau press ID card
- For Taiwan media: Bring confirmation letter and Mainland Travel Permit for Taiwan residents
- Taiwan resident correspondents: Bring press card for resident correspondent and Mainland Travel Permit for Taiwan residents
- For Mainland China media: Bring your confirmation letter, ID card, business card and the new version of press card issued by General Administration of Press and Publication or The State Administration of Radio Film and Television of China
About CES Asia:
Owned and produced by the International CES (Shanghai) Exhibition Co. Ltd. and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.
About International CES (Shanghai) Exhibition Co. Ltd. and CTA:
International CES (Shanghai) Exhibition Co. Ltd. is a wholly foreign-owned enterprise by the Consumer Technology Association (CTA), a trade association representing the $351 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.
About Shanghai Intex:
Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.
June 13-15, Shanghai, China
June 24-27, Barcelona, Spain
September 27, Amsterdam, Netherlands
& Standards Fall Form
October 1-5, Hollywood, CA
October 3, Paris, France
October 15-17, Boston, MA
Unveiled New York
November 8, New York, NY
Unveiled Las Vegas
January 6. 2019, Las Vegas, NV
January 8-11, 2019, Las Vegas, NV
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06 | Tiedote
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 10:00 | Tiedote
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53 | Tiedote
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 17:59 | Tiedote
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme